Nemaura Medical IncFRA Nemaura Stock Report

Nemaura Medical, Inc. operates as a holding company. The company is headquartered in New York City, New York and currently employs 32 full-time employees. The company went IPO on 2014-11-04. The firm is focused on medical technology. The firm through its operating subsidiaries performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and also be used to screen pre-diabetic patients. The sugarBEAT device extracts analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor. The Company’s subsidiaries include Dermal Diagnostics (Holdings) Limited, Dermal Diagnostics Limited and Trial Clinic Limited.